Neuropeptides as therapeutic approach to autoimmune diseases

Current Pharmaceutical Design

Volumn 16, Issue 28, 2010, Pages 3158-3172

  Gonzalez Rey, Elena ^a   Delgado Maroto, Virginia ^a   Souza Moreira, Luciana ^a   Delgado, Mario ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Autoimmunity; Dendritic cells; Inflammation; Neuroimmunology; Neuropeptide; Regulatory t cells; Tolerance

Indexed keywords

ADRENOMEDULLIN; ALPHA INTERMEDIN; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; CHOLECYSTOKININ; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTISTATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FOLLITROPIN; GALANIN; GHRELIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; INTERMEDIN; LUTEINIZING HORMONE; MELANINE CONCENTRATING HORMONE; NEUROKININ; NEUROPEPTIDE; NEUROPEPTIDE Y; NOCICEPTIN; OPIATE PEPTIDE; RENIN; SOMATOSTATIN; SUBSTANCE P; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; UROCORTIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BRAIN INJURY; BRAIN ISCHEMIA; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DENDRITIC CELL; ENDOTOXEMIA; ENTERITIS; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; GINGIVITIS; HEPATITIS; HORMONE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; IMMUNOREGULATION; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MIMICRY; NEPHRITIS; NEUROIMMUNOLOGY; NONHUMAN; OSTEOARTHRITIS; PAIN; PANCREATITIS; PERIODONTITIS; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SEPSIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH3 CELL;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; NEUROIMMUNOMODULATION; NEUROPEPTIDES; VASOACTIVE INTESTINAL PEPTIDE;

EID: 78649871294     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793292465     Document Type: Review

References (120)

1. Goodnow CC. Multistep pathogenesis of autoimmune diseases. Cell 2007; 130: 25-35.
2. Mills KHG. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-55.
3. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells Immunity 2006; 25: 195-201.
4. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol 2005; 5: 343-9.
5. Wan YY, Flavell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev 2006; 212: 114-30.
6. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006, 6: 318-28.
7. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996; 17: 64-102.
8. Elenkov IJ, Wilder RL, Chrousos GP, Vizi S. The sympathetic nerve-An integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
9. Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol 2009; 9: 3-8.
10. Gonzalez-Rey E, Delgado M. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci 2007; 28: 482-91.
11. Lühder F, Lee DH, Gold R, Stegbauer J, Linker RA. Small but powerful: short peptide hormones and their role in autoimmune inflammation. J Neuroimmunol 2009; 217: 1-7.
12. Delgado M, Ganea D. Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain Behav Immun 2008; 22: 1146-51.
13. Brain SD, Cox HM. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 2006; 147: S202-11.
14. Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 2007; 7: 52-63.
15. Fernandes ES, Schmidhuber SM, Brain SD. Sensory-nerve-derived neuropeptides: possible therapeutic targets. Handb Exp Pharmacol 2009; 194: 393-416.
16. Prod'homme T, Weber MS, Steinman L, Zamvil SS. A neuropeptide in immune-mediated inflammation, Y? Trends Immunol 2006; 27: 164-7.
17. Wheway J, Herzog H, Mackay F. The Y1 receptor for NPY: a key modulator of the adaptive immune system. Peptides 2007; 28: 453-8.
18. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004; 56: 249-90.
19. Blalock JE. Proopiomelanocortin and the immune-neuroendocrine connection. Ann NY Acad Sci 1999; 885: 161-72.
20. Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today 1997; 18: 140-5.
21. Gravanis A, Margioris AN. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem 2005; 12: 1503-12.
22. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 563-8.
23. Gonzalez-Rey E, Chorny A, Varela N, Del Moral, RG, Delgado M. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann Rheum Dis 2007; 66: 582-8.
24. Ceriani G, Diaz J, Murphree S, Catania A, Lipton JM. The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation 1994; 1: 28-32.
25. Gonzalez-Rey E, Chorny A, Varela N, O'Valle F, Delgado M. Therapeutic effect of urocortin on collagen-induced arthritis by downregulating inflammatory and Th1 response and inducing regulatory T cells. Arthritis Rheum 2007; 56: 531-43.
26. Gonzalez-Rey E, Chorny A, O'Valle F, Delgado M. Adrenomedullin protects from experimental arthritis by downregulating inflammation and Th1 response and inducing regulatory T cells. Am J Pathol 2007; 170: 263-71.
27. Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M. Cortistatin, a new anti-inflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci USA 2006; 103: 4228-33.
28. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohńs disease. Gut 2006; 55: 824-32.
29. Abad C, Martinez C, Juarranz MG, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003; 124: 961-71.
30. Rajora N, Boccoli G, Catania A, Lipton JM. alpha-MSH modulates experimental inflammatory bowel disease. Peptides 1997; 18: 381-5.
31. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 2006; 130: 1707-20.
32. Poliak S, Mor F, Conlon P, et al. Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitaryadrenal axis and the immune system. J Immunol 1997; 158: 5751-6.
33. Li H, Mei Y, Wang Y, Xu L. Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 2006; 26: 430-7.
34. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, et al. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: downregulation of inflammatory and autoimmune responses. Am J Pathol 2006; 168: 1179-88.
35. Lodde BM, Mineshiba F, Wang J, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's disease. Ann Rheum Dis 2006; 65: 195-200.
36. Bedoui S, Miyake S, Lin Y, et al. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol 2003; 171: 3451-8.
37. Keino H, Kezuka T, Takeuchi M, Yamakawa N, Hattori T, Usui M. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol 2004; 122: 1179-84.
38. Theil MM, Miyake S, Mizuno M, et al. Suppression of experimental autoimmune encephalomyelitis by ghrelin. J Immunol 2009; 183: 2859-66.
39. Taylor AW, Kitaichi N. The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alphamelanocyte stimulating hormone (alpha-MSH) therapy. Brain Behav Immun 2008; 22: 639-46.
40. Rosignoli F, Roca V, Meiss R, et al. VIP and tolerance induction in autoimmunity. Ann NY Acad Sci 2006; 1070: 525-30.
41. Delgado M, Reduta A, Sharma V, Ganea D. VIP/PACAP oppositely affect immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity of CD4+ T cells. J Leukoc Biol 2004; 75: 1122-30.
42. Jiang X, Jing H, Ganea D. VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J Neuroimmunol 2002; 133: 81-94.
43. Delgado M, Gonzalez-Rey E, Ganea D. VIP/PACAP preferentially attract Th2 versus Th1 cells by differentially regulating the production of chemokines by dendritic cells. FASEB J 2004; 18: 1453-5.
44. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ. c- Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol 2004; 172: 7289-96.
45. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J Neuroimmunol 1999; 96: 167-81.
46. Delgado M, Leceta J, Gomariz RP, Ganea D. VIP and PACAP stimulate the induction of Th2 responses by upregulating B7.2 expression. J Immunol 1999; 163: 3629-35.
47. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol 2006; 176: 97-110.
48. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 2002; 16: 1844-6.
49. Pozo D, Anderson P, Gonzalez-Rey E. Induction of alloantigenspecific human T regulatory cells by vasoactive intestinal peptide. J Immunol 2009; 183: 4346-59.
50. Anderson P, Gonzalez-Rey E. Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol Cell Biol 2010; 30: 2537-51.
51. Schulze-Topphoff U, Prat A, Prozorovski T, et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 2009; 15: 788-93.
52. Yadav M, Rosenbaum J, Goetzl EJ. Cutting Edge: Vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 2008; 180: 2772-6.
53. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado, M. Vasoactive intestinal peptide induces CD4+CD25+ regulatory T cells with therapeutic effect on collagen-induced arthritis. Arthritis Rheum 2006; 54: 864-76.
54. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 2006; 36: 318-26.
55. Delgado M, Chorny A, Gonzalez-Rey E, Ganea D. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol 2005; 78: 1327-38.
56. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007; 13: 241-51.
57. Nishida T, Taylor AW. Specific aqueous humor factors induce activation of regulatory T cells. Invest Ophthalmol Vis Sci 1999; 40: 2268-74.
58. Taylor A, Namba K. In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunol Cell Biol 2001; 79: 358-67.
59. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 2005; 102: 13562-7.
60. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 2005; 175: 7311-24.
61. Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of α-MSH and related peptides in the immune system. Ann NY Acad Sci 2003; 994: 133-40.
62. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 2006; 107: 3632-8.
63. Platten M, Youssef S, Hur EM, et al. Blocking angiotensinconverting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 2009; 106: 14948-53.
64. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009; 30: 656-65.
65. Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology 2006; 131: 1799-811.
66. Ng TF, Kitaichi N, Taylor AW. In vitro generated autoimmune regulatory T cells enhance intravitreous allogeneic retinal graft survival. Invest Ophthalmol Vis Sci 2007; 48: 5112-7.
67. Wang J, Zhao R, Zhang F, et al. Control of allograft rejection in mice by applying a novel neuropeptide, cortistatin. Adv Ther 2008; 25: 1331-41.
68. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 2006; 107: 3787-94.
69. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 2010; 184: 2261-71.
70. El Karim IA, Linden GJ, Orr DF, Lundy FT. Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J Neuroimmunol 2008; 200: 11-16.
71. Charnley M, Moir AJG, Douglas CWI, Haycock JW. Antimicrobial action of melanocortin peptides and identification of a novel X-Pro-D/L-Val sequence in gram-positive and gram-negative bacteria. Peptides 2008; 29: 1004-9.
72. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 2008; 180: 8369-77.
73. Madhuri, Shireen T, Venugopal SK, et al. In vitro antimicrobial activity of alpha-melanocyte stimulating hormone against major human pathogen Staphylococcus aureus. Peptides 2009; 30; 1627-35.
74. Delgado M, Anderson P, Garcia-Salcedo JA, Caro M, Gonzalez-Rey E. Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. Cell Death Differ 2009; 16: 406-16.
75. Martinez C, Abad C, Delgado M, et al. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci USA 2002; 99: 1053-8.
76. Szema AM, Hamidi SA, Lyubsky S, et al. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 2006; 291: 880-6.
77. Goetzl EJ, Voice JK, Shen S, et al. Enhanced delayed-type hypersensitivity and diminished immediate type hypersensitivity in mice lacking the inducible VPAC(2) receptor for VIP. Proc Natl Acad Sci USA 2001; 98: 13854-9.
78. Voice JK, Dorsam G, Lee H, Kong Y, Goetzl EJ. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible VIP receptor. FASEB J 2001; 15: 2489-96.
79. Tan YV, Abad C, Lopez R, et al. Pituitary adenylyl cyclaseactivating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2009; 106: 2012-7.
80. Wheway J, Mackay CR, Newton RA, et al. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 2005; 202: 1527-38.
81. Hassani H, Lucas G, Rozell B, Ernfors P. Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling. Am J Physiol Gastrointest Liver Physiol 2005; 288: G550-6.
82. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 2003; 170: 308-14.
83. Dixit VD, Yang H, Cooper-Jenkins A, Giri BB, Patel K, Taub DD. Reduction of T cell-derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation. Blood 2009; 113: 5202-5.
84. Juarranz Y, Gutierrez-Canas I, Santiago B, Carrion M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 2008; 58: 1086-95.
85. Delgado M, Robledo G, Rueda B, et al. Genetic association of Vasoactive intestinal peptide with rheumatoid arthritis. Altered expression and signal in immune cells. Arthritis Rheum 2008; 58: 1010-9.
86. Sun W, Hong J, Zang YC, Liu X, Zhang JZ. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 2006; 18: 1691-700.
87. Paladini F, Cocco E, Cauli A, et al. A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B*2705 in Sardinia. Genes Immun 2008, 9: 659-67.
88. Bangale Y, Karle S, Planque S, et al. VIPase autoantibodies in Fasdefective mice and patients with autoimmune disease. FASEB J 2003; 17: 628-35.
89. Youm YH, Yang H, Sun Y, et al. Deficient ghrelin receptormediated signaling compromises thymic stromal cell microenvi-ronment by accelerating thymic adiposity. J Biol Chem 2009; 284: 7068-77.
90. Dixit VD, Yang H, Sun Y, et al. Ghrelin promotes thymopoiesis during aging. J Clin Invest 2007; 117: 2778-90.
91. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000; 101: 498-503.
92. Davis ME, Pemberton CJ, Yandle TG, et al. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci 2005; 109: 381-8.
93. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339-46.
94. Broglio F, Benso A, Gottero C, et al. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab 2002; 87: 4829-32.
95. Kodama T, Ashitani J, Matsumoto N, Kangawa K, Nakazato M. Ghrelin treatment suppresses neutrophil-dominant inflammation in airways of patients with chronic respiratory infection. Pulm Pharmacol Ther 2008, 21: 774-9.
96. Prasse A, Zissel G, Lutzen N, et al. Inhaled vasoactive intestinal peptide exerts immuno-regulatory effects in sarcoidosis. Published on line on May 4, 2010 as doi:10.1164/rccm.200909-1451OC.
97. Chapter MC, White CM, DeRidder A, Chadwick W, Martin B, Maudsley S. Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther 2010; 125: 39-54.
98. Misaka S, Aoki Y, Karaki S, et al. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: antiinflammatory effect in experimental asthmatic rats. Peptides 2010; 31: 72-8.
99. Onoue S, Misaka S, Ohmori Y, et al. Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability. Eur J Pharm Biopharm 2009; 73: 95-101.
100. Camelo S, Lajavardi L, Bochot A, et al. Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. J Ocul Pharmacol Ther 2009; 25: 9-21.
101. Fernandez-Montesinos R, Castillo PM, Klippstein R, et al. Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles. Nanomedicine 2009; 4: 919-30.
102. Lee DJ, Biros DJ, Taylor AW. Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis. Int Immunopharmacol 2009; 9: 1079-86.
103. Yin P, Luby TM, Chen H, et al. Generation of expression constructs that secrete bioactive alphaMSH and their use in the treatment of experimental autoimmune encephalomyelitis. Gene Ther 2003; 10: 348-55.
104. Herrera JL, Fernandez-Montesinos R, Gonzalez-Rey E, Delgado M, Pozo D. Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. Ann NY Acad Sci 2006; 1070: 337-41.
105. Delgado M, Toscano MG, Benabdellah K, et al. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthritis Rheum 2008; 58: 1026-37.
106. Toscano MG, Delgado M, Kong W, Martin F, Skarica M, Ganea D. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 2010; 18: 1035-45.
107. Han D, Tian Y, Zhang M, Zhou Z, Lu J. Prevention and treatment of experimental autoimmune encephalomyelitis with recombinant adeno-associated virus-mediated alpha-melanocyte-stimulating hormone-transduced PLP139-151-specific T cells. Gene Ther 2007; 14: 383-95.
108. Miksa M, Wu R, Cui X, et al. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma. J Immunol 2007; 179: 6263-6272.
109. Blakeney JS, Fairlie DP. Nonpeptide ligands that target peptideactivated GPCRs in inflammation. Curr Med Chem 2005; 12: 3027-42.
110. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research biological, chemical and therapeutic aspects. Nat Rev Drug Disc 2003; 2: 999-1017.
111. van Op den Bosch J, Adriaensen D, Van Nassauw L, Timmermans JP. The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review. Regul Pept 2009; 156: 1-8.
112. van Hagen PM, Dalm VA, Staal F, Hofland LJ. The role of cortistatin in the human immune system. Mol Cell Endocrinol 2008; 286: 141-7.
113. Krantic S. Peptides as regulators of the immune system: emphasis on somatostatin. Peptides 2000; 21: 1941-64.
114. Brod SA, Hood ZM. Ingested (oral) alpha-MSH inhibits acute EAE. J Neuroimmunol 2008; 193: 106-12.
115. Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 2005; 7: 253-69.
116. Foey AD, Field S, Ahmed S, et al. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther 2003; 5: 317-28.
117. Moffatt JD, Lever R, Page CP. Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice. FASEB J 2006; 20: 1877-9.
118. Ganea D, Delgado M. The neuropeptides VIP/PACAP and T cells: inhibitors or activators? Curr Pharm Des 2003; 9(12): 997-1004.
119. Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 2007; 13(11): 1113-39.
120. Snoek SA, Borensztajn KS, van den Wijngaard RM, de Jonge WJ. Neuropeptide receptors in intestinal disease: physiology and therapeutic potential. Curr Pharm Des 2010; 16(9): 1091-105.